Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
46.19 USD | -1.97% | -12.72% | -23.23% |
Apr. 19 | US FDA mandates label updates on CAR-T cancer therapies | RE |
Apr. 17 | Scotiabank Upgrades Legend Biotech to Sector Outperform From Sector Perform, Price Target is $65 | MT |
Chart calendar Legend Biotech Corporation
Upcoming events on Legend Biotech Corporation
Past events on Legend Biotech Corporation
2024-03-11 08:00 am | Q4 2023 Earnings Call |
2024-03-11 07:00 am | Q4 2023 Earnings Release |
2024-01-09 05:15 pm | JPMorgan Healthcare Conference |
2023-12-11 09:00 pm | American Society of Hematology Meeting - Abstract #4866 |
2023-12-11 09:00 pm | American Society of Hematology Meeting - Abstract #5083 |
2023-12-11 07:30 pm | American Society of Hematology Meeting - Abstract #1021 |
2023-12-11 07:30 pm | American Society of Hematology Meeting - Abstract #1063 |
2023-12-10 09:00 pm | American Society of Hematology Meeting - Abstract #3501 |
2023-12-09 08:30 pm | American Society of Hematology Meeting - Abstract #2141 |
2023-12-09 08:30 pm | American Society of Hematology Meeting - Abstract #2099 |
2023-11-20 08:00 am | Q3 2023 Earnings Call |
2023-11-20 06:00 am | Q3 2023 Earnings Release |
2023-09-21 09:30 am | Annual General Meeting |
2023-08-15 08:00 am | Q2 2023 Earnings Call |
2023-08-15 06:00 am | Q2 2023 Earnings Release |
2023-06-14 11:00 am | Goldman Sachs Global Healthcare Conference |
2023-06-11 06:00 am | European Hematology Association Hybrid Congress - Abstract #S202 |
2023-06-10 08:45 am | European Hematology Association Hybrid Congress - Abstract #S100 |
2023-06-09 12:00 pm | European Hematology Association Hybrid Congress - Abstract #P922 |
2023-06-09 12:00 pm | European Hematology Association Hybrid Congress - Abstract #P874 |
Annual results
Fiscal Period | December | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 75,7 51,5 46.91% | 89,8 66,9 34.16% | 117 132 -11.08% | 285 296 -3.82% | 589 |
EBITDA Million USD | Released Forecast Spread | -221 -201 -9.63% | -361 -274 -31.38% | -443 -305 -45.35% | -392 -420 6.65% | -320 |
EBIT Million USD | Released Forecast Spread | -229 -216 -5.91% | -373 -335 -11.2% | -456 -424 -7.4% | -413 -458 9.85% | -335 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -308 -329 6.5% | -386 -355 -8.74% | -446 -437 -1.97% | -520 -487 -6.75% | -318 |
Net income Million USD | Released Forecast Spread | -303 -325 6.69% | -386 -341 -13.32% | -446 -437 -2.06% | -518 -482 -7.55% | -317 |
EPS USD | Released Forecast Spread | -1,28 -1,38 7.16% | -1,37 -1,78 22.93% | -1,40 -1,38 -1.24% | -1,47 -1,65 10.96% | -1,07 |
Announcement Date | 18/03/21 | 18/03/22 | 30/03/23 | 11/03/24 | - |
Quarterly results
Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 39,0 14,2 174.23% | 40,8 16,7 144.96% | 12,0 37,2 -67.81% | 27,7 | 31,3 | 36,3 39,8 -8.76% | 73,3 56,2 30.39% | 96,0 99,5 -3.51% | 79,5 95,7 -16.93% | 149 | 125 | 133 | 180 | 187 |
EBITDA Million USD | Released Forecast Spread | -114 -117 2.43% | -116 -74,4 -55.99% | -85,0 | -80,6 | -160 | -53,6 -132 59.36% | -56,9 | -112 | -99,4 | -85,8 | -74,1 | |||
EBIT Million USD | Released Forecast Spread | -117 -103 -14.12% | -76,0 -137 44.38% | -126 -90,7 -38.42% | -110 | -132 | -107 -155 31.2% | -104 -140 25.56% | -56,8 -122 53.37% | -141 -124 -13.65% | -59,7 | -88,7 | -100 | -90,4 | -82,8 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -88,3 -102 13.73% | -41,1 -137 69.93% | -193 -121 -59.16% | -113 | -135 | -112 -155 27.94% | -199 -130 -53.17% | -62,5 -109 42.44% | -147 -122 -19.94% | -67,8 | -92,0 | -97,7 | -84,2 | -85,5 |
Net income Million USD | Released Forecast Spread | -88,3 -98,2 10.04% | -41,1 -137 69.93% | -193 -121 -59.29% | -113 | -135 | -112 -153 26.61% | -199 -130 -53.33% | -62,2 -109 42.75% | -145 -112 -29.27% | -67,6 | -91,8 | -97,4 | -83,5 | -85,6 |
EPS USD | Released Forecast Spread | -0,30 -0,44 31.82% | -0,13 -0,49 73.47% | -0,62 -0,39 -58.71% | -0,35 | -0,42 | -0,34 -0,45 25.03% | -0,57 -0,37 -52.87% | -0,17 -0,31 44.39% | -0,40 -0,30 -31.35% | -0,18 | -0,28 | -0,29 | -0,24 | -0,24 |
Announcement Date | 18/03/22 | 01/06/22 | 17/02/23 | - | - | 18/05/23 | 15/08/23 | 20/11/23 | 11/03/24 | - | - | - | - | - |
Past sector events for Legend Biotech Corporation
2024-04-17 | BEIJING KAWIN TECHNOLOGY SHARE-HOLDING CO., LTD.: Q1 2024 Earnings Release (Projected) |
2024-04-17 | JIANGSU YAHONG MEDITECH CO., LTD.: Q4 2023 Earnings Release |
2024-04-12 | SINOCELLTECH GROUP LIMITED: Q4 2023 Earnings Release |
2024-04-10 07:00 am | NURIX THERAPEUTICS, INC.: Q1 2024 Earnings Release |
2024-04-08 | MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.: Q4 2023 Earnings Release |
2024-04-02 03:06 am | TAIMED BIOLOGICS INC.: March 2024 Sales and Revenue Release |
2024-03-31 | PEPTRON, INC.: Q4 2023 Earnings Release (Projected) |
2024-03-31 | BIONEER CORPORATION: Q4 2023 Earnings Release (Projected) |
2024-03-29 08:30 am | INNOCARE PHARMA LIMITED: Q4 2023 Earnings Release |
2024-03-28 | BIO-THERA SOLUTIONS, LTD.: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- LEGN Stock
- Calendar Legend Biotech Corporation